A view from the Center

>

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

Digital tech and strong patient-advocacy partnerships could be a win-win-win for pharma, advocacy groups, and patients

by Jonathan Fox, Specialist leader, Deloitte Consulting LLP

I’m in Philadelphia this week for the annual EyeForPharma conference where I’ll be moderating a panel looking into how pharmaceutical companies and advocacy groups can take their relationship to the next level. Both sides have something to gain, and the patient could be the biggest winner.

Pharmaceutical companies often collaborate with patient advocacy groups,

Read more

As interest in oncology grows, real-world data could help biopharma firms improve clinical research, reduce costs

by Brett J. Davis, General Manager & Principal | ConvergeHealth by Deloitte, Deloitte Consulting LLP

Early this year, I attended the annual J.P. Morgan Healthcare conference where investors and biopharmaceutical company executives were excited about the growth of personalized therapies—particularly in oncology. This optimism was somewhat tempered by some of the many challenges in oncology research and development (R&D) and bringing high-cost therapies to market. However, advances in digital health,

Read more

Health and research in 2019: Five trends to watch

by Margaret Anderson, Managing Director, Deloitte Consulting LLP

There is something about a new year that gives us a clearer vantage point on the trends that might lie ahead. A new year might be an artificial demarcation point, but I use it to reflect on where the health care and innovation market is now, and where it could be headed.

The exponential promise that exists in the life sciences and health care sectors is unprecedented.

Read more

In the absence of drug rebates, new alternatives are likely to emerge

by Joseph M. Coppola, Managing Director, Life Sciences Commercial and Market Access Practice Leader, Deloitte Consulting LLP

The administration’s efforts to reduce prescription drug spending have put drug rebates in the spotlight. If rebates lose their safe-harbor status—as my colleague George Van Antwerp outlined in his recent blog—other models are likely to emerge to replace them. At least initially, any change to the rebate model is likely to be limited to Medicare Part D,

Read more

Disruptive potential of genomics could prompt life sciences companies to accelerate deal-making

by Susan Dettmar, principal, US M&A consultative services leader, and Kushan Biswas, Life Sciences M&A senior manager, Deloitte Consulting LLP

The ability to transform genomic information into effective diagnostics and therapies might represent the future of medicine. This potential is inspiring a new era of deal-making among biopharmaceutical and genomics companies that want to achieve a leadership position in next-generation therapies.

Within the next 12-18 months, 85 percent of global life sciences firms expect to leverage genomics data—either purchased data or through partnerships,

Read more

The future of drug rebates: Are they to be or not to be?

by George Van Antwerp, Managing Director, Deloitte Consulting LLP

Nearly half of all Americans (49 percent) have at least one prescription drug, and 12 percent of the population has five or more, according to 2017 data from the Centers for Drug Control and Prevention (CDC). In 2016, $329 billion was spent on prescription drugs—an increase of nearly 30 percent from 2010.1

With so much money at stake,

Read more